Acute septic arthritis is a rare, but potentially devastating disease. The treatment is initiated intravenously, but can be safely switched to oral after 2–4 days providing large doses of a well-absorbing antibiotic and, for time-dependent antibiotics, 4 times-a-day administration are used. Empiric treatment should always cover Staphylococcus aureus and common respiratory pathogens, whereas Kingella kingae and Salmonella are important only regionally. Studies conducted by our group have shown that a total course of 10 days may suffice for previously healthy children in a Western setting. Treatment of neonates, patients with immunodeficiency or cases caused by methicillin-resistant S. aureus, may deserve a different approach.
From the *Department of Orthopaedics and Traumatology, University of Turku, Turku University Hospital, Turku; and †Department of Pediatrics, University of Helsinki, Children’s Hospital, Helsinki University Central Hospital, Helsinki, Finland.
M.P. received funding support from Foundation for Pediatric Research, Finland, and Turku University Hospital Foundation for Education and Research. H.P. received funding support from Foundation for Pediatric Research, Finland. H.P. works as a consultant for Serum Institute of India Ltd. The authors have no other funding or conflicts of interest to disclose.
Address for correspondence: Markus Pääkkönen, MD, Turku University Hospital, PO Box 52, 20521 Turku, Finland. E-mail: Markus.Paakkonen@helsinki.fi.
Acute septic arthritis (SA) in children is most often of hematogenous origin. In a Western setting, the annual incidence is around 4:100,000 children.1 Boys are more prone than girls. Hip, knee and ankle joints are frequently affected. Staphylococcus aureus is the most common causative agent, followed by respiratory pathogens Streptococcus pyogenes, Streptococcus pneumoniae and Haemophilus influenzae type b (Hib).2–4 Kingella kingae and Salmonella spp. are regionally important agents.
An acutely swollen, red, painful joint combined with high fever signal a potential SA. Movement is limited in the affected joint and symptoms tend to increase progressively. The child refuses weight-bearing when the lower limb is involved. This classical pattern is often seen in cases caused by S. aureus, but in contrast SA caused by K. kingae may develop insidiously. The characteristic signs of SA may be difficult to detect in a child with a septic hip joint, but neonates often assume a characteristic position with the hip joint flexed and externally rotated. Serum C-reactive protein (CRP) and erythrocyte sedimentation rate are sensitive in diagnostics, but erythrocyte sedimentation rate alternates too slowly to be of much use in the follow-up.1,5 Procalcitonin challenges CRP, but the measurement requires more time (CRP only needs a few minutes) and is more expensive.1 Ultrasound detects joint effusion and can guide a diagnostic joint puncture, which should always be attempted.4 In younger children, the procedure is performed under anesthesia. A purulent joint discharge, positive Gram stain and/or bacterial culture confirm the diagnosis, whereas a traditional synovial fluid cytology is often difficult to interpret due to considerable overlap between different types of arthritides.1 In addition to conventional agar plates, aerobic blood culture bottles are required to detect K. kingae, and although special techniques are not required, an automated system with capability to detect this pathogen should be used.
Intravenous antibiotic is instituted almost always before the causative agent has been identified by cultures. The role of S. aureus is overwhelming and its local resistance pattern dictates the choice of antibiotic.1 Large doses of clindamycin (≥40 mg/kg/day divided in 4 equal doses, qid) or a first-generation cephalosporin (≥150 mg/kg/day, qid) have been our choices against methicillin-sensitive S. aureus strains,5 but staphylococcal penicillins would likely work as well unless exceptionally large oral doses lead to diarrhea. The same dosing applies to both parenteral and oral administration. If a first-generation cephalosporin is not available for intravenous administration, a second-generation cephalosporin may also be used as a substitute.
Clindamycin continues to be effective against most methicillin-resistant S. aureus (MRSA) strains.6 Clindamycin and vancomycin are ineffective against K. kingae for which β-lactams are good choices. Interestingly, cheap trimethoprim-sulfamethoxazole is experiencing a renaissance in the treatment of MRSA.7 Vancomycin should be considered if resistance to clindamycin is common.2,8 An expensive alternative is linezolid.8 Pneumococcus and S. pyogenes do not usually cause problems in terms of resistance when high doses are used. Hib has largely vanished from the etiology of SA in regions with large-scale vaccinations. If this is not the case, unvaccinated children younger than 5 years should receive concomitant ampicillin/or amoxicillin until the agent is identified.5
The optimal duration of intravenous and oral treatment has been disputed for decades.3,4 Severity of complications associated with SA has led many authors to recommend months’ long medications with an initial intravenous period even for several weeks.1,2,4 In a recent study, the majority of cases of SA were treated 3 to 5 days intravenously followed by 3 weeks of oral antibiotics.3 Current Infectious Diseases Society of America guideline for MRSA SA states that the exact duration of therapy should be individualized, but typically a minimum of 3 to 4 weeks is recommended.8 In our prospective, randomized trial, a total of 10 days of high-dose clindamycin or a first-generation cephalosporin was sufficient in uncomplicated cases caused by methicillin-sensitive S. aureus.4,5 The treatment was started intravenously, usually for no more than 2 to 4 days, and the course was completed orally to a total duration of 10 days.
One lesson learned from our largest-to-date trial4 was that CRP was of great value, not only in the diagnostics but also in monitoring the course of illness, and in the decision to discontinue antibiotics. Our cutoff level was set at 20 mg/L; once this level was reached, the medication was stopped, provided most symptoms and signs had subsided. This occurred usually in a week or so. In cases of concomitant osteomyelitis, we routinely extended the total course to 20 days. Our treatment algorithm is depicted in Figure 1.
It should, however, be kept in mind that a 10-day treatment course is not an universally accepted standard of care, 1 of the reasons being that it has not yet been tested in MRSA cases. We therefore recommend, at least so far, our 10-day course only for previously healthy children beyond neonatal age whose SA is not due to agent such as Salmonella (uncommon in Western settings). These patients, as the neonates and those with an immunocompromise, likely need treatment to be individually tailored. Nonsteroidal anti-inflammatory agents are administered at the discretion of the attending physician. Adjuvant dexamethasone seems to slightly quicken recovery without reducing the frequency or extent of complications.9
Because a dismal outcome—death, avascular necrosis of the femoral head, arthrosis, an so on—may still be the ultimate outcome of complicated SA, some further aspects have to be taken into account. The prognosis worsens if a child presents late after significant cartilage destruction has developed. Already a delay of more than 5 days from the onset of symptoms seems to affect adversely on recovery,4 and such a wait is regrettably common in developing countries. In the United States, the MRSA-USA300 strain and Panton-Valentine leukocidin gene have associated with a severe disease with a longer duration of fever.2 Extended antibiotic treatment for MRSA has been recommended, but prospective trials are lacking.2,8 In our series, methicillin-sensitive S. aureus cases were treated as those caused by other agents, and there was no difference in outcome.10
OUR PRACTICAL APPROACH TO TREATMENT AND CONCLUSIONS
Our approach to potential childhood SA is straightforward: a diagnostic joint aspiration (under anesthesia at least in younger children) is performed and if SA is diagnosed, clindamycin or a first-generation cephalosporin is instituted, first intravenously for a few days, then orally to a minimum of 10 days. However, exceptionally large doses (≥40 or ≥150 mg/kg/day till a maximum daily dose of 2–4 g or~3 g, respectively) and a qid regimen are used for these time-dependent antibiotics.1,4,5 Once CRP has declined below 20 mg/L, the antibiotic can usually be discontinued if most symptoms and signs are alleviated. Patients who have not responded uneventfully may benefit from prolonged treatment. Because sequelae may develop insidiously, a follow-up for at least a year is well-founded.4,5
All this said, complications or deviations from the expected course of disease occur in medicine. However, the difficult-to-treat cases present a minority and can usually be detected by simple tools such as sequential CRP determinations.4
1. Pääkkönen M, Peltola H. Management of a child with suspected acute septic arthritis. Arch Dis Child. 2012;97:287–292
2. Carrillo-Marquez MA, Hulten KG, Hammerman W, et al. USA300 is the predominant genotype causing Staphylococcus aureus
septic arthritis in children. Pediatr Infect Dis J. 2009;28:1076–1080
3. Jagodzinski NA, Kanwar R, Graham K, et al. Prospective evaluation of a shortened regimen of treatment for acute osteomyelitis and septic arthritis in children. J Pediatr Orthop. 2009;29:518–525
4. Peltola H, Pääkkönen M, Kallio P, et al.Osteomyelitis-Septic Arthritis (OM-SA) Study Group. Prospective, randomized trial of 10 days versus 30 days of antimicrobial treatment, including a short-term course of parenteral therapy, for childhood septic arthritis. Clin Infect Dis. 2009;48:1201–1210
5. Peltola H, Pääkkönen M, Kallio P, et al.OM-SA Study Group. Clindamycin vs. first-generation cephalosporins for acute osteoarticular infections of childhood–a prospective quasi-randomized controlled trial. Clin Microbiol Infect. 2012;18:582–589
6. Martínez-Aguilar G, Hammerman WA, Mason EO Jr, et al. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus
in children. Pediatr Infect Dis J. 2003;22:593–598
7. Messina AF, Namtu K, Guild M, et al. Trimethoprim-sulfamethoxazole therapy for children with acute osteomyelitis. Pediatr Infect Dis J. 2011;30:1019–1021
8. Liu C, Bayer A, Cosgrove SE, et al.Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus
infections in adults and children. Clin Infect Dis. 2011;52:e18–e55
9. Harel L, Prais D, Bar-On E, et al. Dexamethasone therapy for septic arthritis in children: results of a randomized double-blind placebo-controlled study. J Pediatr Orthop. 2011;31:211–215
10. Pääkkönen M, Kallio PE, Kallio MJ, et al. Management of osteoarticular infections caused by Staphylococcus aureus
is similar to that of other etiologies: analysis of 199 staphylococcal bone and joint infections. Pediatr Infect Dis J. 2012;31:436–438
septic arthritis; child; Staphylococcus aureus; clindamycin; C-reactive protein